Breast Cancer Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Breast Cancer Treatment Market by Drug Class (Anthracyclines, Antimetabolites, Epothilones, Taxanes, Alkylating agents, Hormonal therapy, Aromatase inhibitors, Selective Oestrogen-receptor modulators), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Latin America, Europe, Asia Pacific and Middle East and Africa)

 

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Breast Cancer Treatment market size was valued at US$ 19.5 Billion in 2020 and is expected to grow US$ 33.20 Billion by 2027 at a CAGR of 7.9% during the forecast period. Breast cancer is the disease occurs when uncontrolled growth of malignant cells in the breast tissue that is most commonly occurs in female than men. Treatment of breast cancer depends on various factors such as the type of breast cancer, the size of a tumour, stage of breast cancer and the grade of cancer cells. The breast cancer can be treated by various therapies such as radiation therapy, chemotherapy, hormone therapy, targeted therapy and bone-directed therapy. The common signs and symptoms associated with breast cancer include change in the breast shape, forming of lumps in the breast, dimpling of skin, and red scaly patches on the skin. In severe conditions, bone pain, swelling of lymph nodes, problems in respiration, and yellow skin may appear. The breast cancer commonly occurs due to drinking alcohol, being female, obesity, ionizing radiation, family history and older age among others. Breast cancer is diagnosed by taking a biopsy of lump. After the diagnosis, further tests are carried to determine the cancer stage and suitable treatment for the disease. In July 2017, U.S. FDA Approved Puma Biotechnology’s Nerlynx (Neratinib) for the treatment of HER2-positive breast cancer in early stag. In July 2017, AstraZeneca received the approval from European Commission (EC) for  Faslodex (fulvestrant) for the breast cancer treatment


Breast Cancer Treatment Market

MARKET SUMMARY
-
7.9% CAGR
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– 7.9%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Breast Cancer Treatment Market Analysis

  • Global breast cancer treatment market is in developing stage, owing to increase in the prevalence rate of breast cancer disease. According to World Health Organization, about 2000 new cases in men and approximately 200,000 new breast cancer cases in women are diagnosed.
  • Most of the pharmaceutical companies in breast cancer treatment market are focus on research and development activities, strategic collaborations, acquisitions & mergers, and product launches for the development of their revenue in the breast cancer treatment market.
  • For instance, in March 2017, Novartis has received FDA approval for its drug kisqali (ribociclib, LEE011) used as first-line treatment for the HR+/HER2 metastatic breast cancer along with aromatase inhibitor. Similarly, In September 2013, The U.S. Food and Drug Administration granted the accelerated approval for Perjeta (pertuzumab) used in the treatment of early stage breast cancer treatment before surgery. The innovation of some innovative therapy with better success rate is expected to offer a good opportunity for breast cancer treatment market.
Market Leaders
  • AstraZeneca (U.K.)
  • GlaxoSmithKline plc (U.K.)
  • Eli Lilly and Company (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Pfizer, Inc (U.S.)
  • Sun Pharmaceutical Industries Ltd (India)
  • Actavis, Inc. (U.S.)
  • Bristol-Myers Squibb Company (U.S.)
  • Bayer AG (Germany)
  • Teva Pharmaceutical Industries. Ltd. (Israel)
  • Puma Biotechnology, Inc. (U.S.)
  • OncoGenex Pharmaceuticals Inc. (U.S.)
Breast Cancer Treatment Market

Drivers and Restraints

The global breast cancer treatment market is expected to increase with significant CAGR due to increasing prevalence and incidence of breast cancer cases. Rising awareness about breast cancer stages and treatment, government initiatives, and improving healthcare infrastructure are driving the breast cancer treatment market. Moreover, the rise in the healthcare expenditure, increase in the diabetic and obese population, increased spending on medicines, increasing consumption of alcohol and tobacco, and rising female population age of 65 years and above are expected to fuel the market over the forecast period.

Furthermore, increase in the investments in research and developments, development of targeted drug delivery systems, and advancement in cancer biology & pharmacology might boost the market. However, drug development challenges in developing countries, long-term side effects of drugs, high costs associated with drug development, stringent regulatory guidelines, and patent expiry of drugs might hamper the growth of the market in the forecast years.


Breast Cancer Treatment Market

North America dominates the market

Geographically, the breast cancer drugs market segmented into following regions Viz. Europe, Latin America, Middle East and Africa, Asia-Pacific, and North America. North America dominates the breast cancer treatment market mainly attributed to high prevalence of breast cancer disease, increase in female aging population, and favourable government initiatives for the treatment. Furthermore, increase in the healthcare infrastructure, favourable reimbursement policies, and high incorporation of targeted therapies also propel the breast cancer treatment market growth in North America region. Europe holds a major share in breast cancer treatment market owing to rise in the prevalence and incidence of breast cancer cases (According to World Cancer Research Fund International, nearly 1.7 million new breast cancer cases were diagnosedin 2012. In the UK itself, 53,696 new cases were diagnosed in 2013).

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2015-2020) and forecast (2021-2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Breast Cancer Treatment Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • AstraZeneca (U.K.)
  • GlaxoSmithKline plc (U.K.)
  • Eli Lilly and Company (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Pfizer, Inc (U.S.)
  • Sun Pharmaceutical Industries Ltd (India)
  • Actavis, Inc. (U.S.)
  • Bristol-Myers Squibb Company (U.S.)
  • Bayer AG (Germany)
  • Teva Pharmaceutical Industries. Ltd. (Israel)
  • Puma Biotechnology, Inc. (U.S.)
  • OncoGenex Pharmaceuticals Inc. (U.S.)

Description

Breast Cancer Treatment market size was valued at US$ 19.5 Billion in 2020 and is expected to grow US$ 33.20 Billion by 2027 at a CAGR of 7.9% during the forecast period. Breast cancer is the disease occurs when uncontrolled growth of malignant cells in the breast tissue that is most commonly occurs in female than men. Treatment of breast cancer depends on various factors such as the type of breast cancer, the size of a tumour, stage of breast cancer and the grade of cancer cells. The breast cancer can be treated by various therapies such as radiation therapy, chemotherapy, hormone therapy, targeted therapy and bone-directed therapy. The common signs and symptoms associated with breast cancer include change in the breast shape, forming of lumps in the breast, dimpling of skin, and red scaly patches on the skin. In severe conditions, bone pain, swelling of lymph nodes, problems in respiration, and yellow skin may appear. The breast cancer commonly occurs due to drinking alcohol, being female, obesity, ionizing radiation, family history and older age among others. Breast cancer is diagnosed by taking a biopsy of lump. After the diagnosis, further tests are carried to determine the cancer stage and suitable treatment for the disease. In July 2017, U.S. FDA Approved Puma Biotechnology’s Nerlynx (Neratinib) for the treatment of HER2-positive breast cancer in early stag. In July 2017, AstraZeneca received the approval from European Commission (EC) for  Faslodex (fulvestrant) for the breast cancer treatment

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX